The Experts below are selected from a list of 8640 Experts worldwide ranked by ideXlab platform
Kazuo Tsubota - One of the best experts on this subject based on the ideXlab platform.
-
lacrimation and salivation are not related to Lymphocytic Infiltration in lacrimal and salivary glands in mrl lpr lpr mice
Advances in Experimental Medicine and Biology, 1998Co-Authors: Hiromi Fujita, Tsutomu Takeuchi, Tsutomu Fujihara, Ichiro Saito, Kazuo TsubotaAbstract:Sjogren’s syndrome (SS) is an autoimmune disease characterized by Lymphocytic Infiltration into salivary and lacrimal glands leading to xerostomia and keratoconjunctivitis sicca.1–5 Lymphocytic Infiltration into these glands has been demonstrated in several kinds of autoimmune mice, such as MRL/MP—+/+ (MRL/+), MRL/MP~lpr/lpr (MRL/lpr), NZB, NZB/W Fl hybrid, and NOD.6–8 Among these strains, MRL/lpr mice may be one of the best models for Sjogren’s syndrome, since marked Infiltration of lymphocytes has been reported in lacrimal and salivary glands, which is indistinguishable from human disease.6 The infiltrated lymphocytes in the glands of MRL/lpr mice were largely CD4+ T-cells with lesser numbers of CD8+T-cells and B-cells,8–11 but CD4- CD8- double-negative T-cells were rarely detected.
-
decreased reflex tearing is associated with Lymphocytic Infiltration in lacrimal glands
The Journal of Rheumatology, 1996Co-Authors: Kazuo Tsubota, Tsutomu Fujihara, Shigeo Katagiri, Tsutomu TakeuchiAbstract:Objective. To investigate whether reflex tearing measured by the Schirmer test with nasal stimulation is better correlated with Lymphocytic Infiltration of the lacrimal gland and is thus a more appropriate test for Sjogren's syndrome (SS). Methods. 272 patients with dry eye (age 55.5 ± 13.5 years) with regular Schirmer test results <10 mm were recruited for the study. They were divided into 2 groups depending on the results of the Schirmer test with nasal stimulation. 24 age and sex matched patients from each group were selected for lacrimal gland biopsy and 10 patients for salivary gland biopsy, and the levels of systemic autoantibodies and degrees of ocular surface staining and Lymphocytic Infiltration of the lacrimal and salivary glands were compared. Results. Of the 272 patients, 187 (68.8%) had good reflex tearing (GT) and 85 (31.2%) had poor reflex tearing (PT). There were no significant differences in the age or sex of the 2 groups. Lymphocytic Infiltration of the lacrimal gland was observed in 7 GT cases and 22 PT cases out of 24 cases. Lymphocytic Infiltration of the salivary gland was also higher in the PT (6 of 10) than the GT group (2 of 10). Conclusion. Evaluation of reflex tearing by the Schirmer test with nasal stimulation identifies 2 groups of patients with dry eye. Those with poor reflex tearing were more likely to have autoantibodies and Lymphocytic Infiltration of the exocrine glands consistent with SS.
-
Lymphocytic Infiltration of the conjunctiva and the salivary gland in sjogren s syndrome
Archives of Ophthalmology, 1993Co-Authors: Taiichi Hikichi, Akitoshi Yoshida, Kazuo TsubotaAbstract:To the Editor. —Diagnosis of Sjogren's syndrome (SS) is based on clinical examination of the eyes and mouth, and biopsy of the minor salivary glands. The principal histologic changes in the minor salivary glands are Lymphocytic Infiltration. Although it was naturally supposed that keratoconjunctivitis sicca is due to the desiccation resulting from lack of tears, Pflugfelder et al 1 presented the hypothesis that the conjunctiva is also directly affected in SS. We report herein the Lymphocytic Infiltration of the conjunctiva in patients with SS by brush cytologic study of the conjunctiva. 2 Patients with SS (two men and 38 women with a mean age of 53.1±7.4 years), patients with keratoconjunctivitis sicca without any systemic abnormalities (11 women with a mean age of 55.3±3.2 years), and normal subjects (one man and nine women with a mean age of 50.1±8.5 years) were recruited for this study. Using the cytobrush with the
Michalis Liontos - One of the best experts on this subject based on the ideXlab platform.
-
217 the impact of chemotherapy response score and Lymphocytic Infiltration in patients with ovarian cancer treated with neoadjuvant chemotherapy
International Journal of Gynecologic Cancer, 2021Co-Authors: I Rodolakis, Michalis Liontos, Maria Sotiropoulou, Anastasia Prodromidou, Dimitrios Haidopoulos, A Bamias, Dimitrios Loutradis, N Thomakos, A RodolakisAbstract:Introduction/Background* Neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) represents an alternative approach to primary debulking for the management of advanced epithelial ovarian cancer (EOC) with comparable survival outcomes. Histopathologic examination of the IDS specimens and the evaluation of Chemotherapy Response Score (CRS) have been proposed as significant markers of response to NACT. The aim of the prsent study was to evaluate the prognostic significance of CRS in OC patients treated with NACT. Methodology A single institution retrospective analysis of patients with OC stage ≥III who were selected to receive NACT from 2011 to 2018 was performed. Omental and ovarian samples were assessed for the evaluation of CRS according to International Collaboration on Cancer Reporting (ICCR) recommendation. Lymphocytic Infiltration, presence of necrosis and mitotic index were also assessed. Result(s)* The final analysis included a total of 60 patients with median age of 65 years at diagnosis. Omentum and ovarian samples of the included patients revealed a CRS 3 in 20 and 10 patients, respectively. Patients with CRS3 at omentum had significantly prolonged median progression free survival (PFS) compared to CRS1 and CRS2 (19 vs 10 vs 15 months, respectively, p=0.002), while no difference was observed in the respective OS among the groups (42 vs 28 vs 32.3 months, respectively). Lymphocytic Infiltration in pre-treatment biopsies was related to improved PFS and OS (log-rank p =0.01 and p=0.015, respectively). No effect on either PFS or OS was observed in patients who received bevacizumab post-IDS, while in patients with Lymphocytic Infiltration bevacizumab negatively affected PFS. Conclusion* CRS seems to play a key role in the prediction of the postoperative course of EOC patients who received NACT and IDS. However, further studies are warranted to decipher the exact role of CRS and Lymphocytic Infiltration so as to personalize the treatment of EOC patients.
-
Lymphocytic Infiltration and chemotherapy response score as prognostic markers in ovarian cancer patients treated with neoadjuvant chemotherapy
Gynecologic Oncology, 2020Co-Authors: Michalis Liontos, Maria Sotiropoulou, Maria Kaparelou, Kimon Tzannis, George Tsironis, Anastasios Kyriazoglou, Anna Tsiara, Roubini Zakopoulou, Konstantinos Koutsoukos, Flora ZagouriAbstract:Abstract Neoadjuvant Chemotherapy (NACT) followed by Interval Debulking Surgery (IDS) is an accepted frontline treatment in patients with advanced Epithelial Ovarian Cancer (EOC). Histopathologic assessment of tumor post NACT may provide a surrogate for response to treatment. The present study aims to characterize the pathological response and to examine its prognostic significance in these patients. Medical records of women with EOC treated in our institution from 2011 to 2016 were retrospectively identified. IDS specimens were reviewed by study pathologist and Chemotherapy Response Score (CRS), Lymphocytic Infiltration, necrosis and mitosis were assessed. 55 patients with EOC treated with NACT were identified and 48 had complete clinical and pathological data. Median age was 63 years. CRS assessed at omentum predicted PFS when adjusted for age, stage, debulking status (complete, optimal, suboptimal) and post IDS bevacizumab administration (mPFS CRS 1 vs 2 vs 3: 10.3–14–18.7 months 95% CI [7.4–15.7], [12.2–22.9], [13.5–31.3]). Presence of Lymphocytic Infiltration was associated with improved OS (log-rank test P = 0.015). Post IDS bevacizumab was associated with shorter PFS in patients with Lymphocytic Infiltration. BRCA status was known for 25 patients and presence of BRCA1/2 mutations was strongly correlated with Lymphocytic Infiltration (P = 0.011) but not CRS omentum (P = 0.926). Our study confirms the predictive value of CRS in EOC patients treated with NACT and IDS, but also demonstrates the prognostic significance of Lymphocytic Infiltration as well as its possible interaction with bevacizumab treatment.
Hajime Tamai - One of the best experts on this subject based on the ideXlab platform.
-
the correlation between papillary thyroid carcinoma and Lymphocytic Infiltration in the thyroid gland
The Journal of Clinical Endocrinology and Metabolism, 1995Co-Authors: Sunao Matsubayashi, Keisuke Kawai, Y Matsumoto, T Mukuta, Tetsuya Morita, K Hirai, Fumio Matsuzuka, K I Kakudoh, Kanji Kuma, Hajime TamaiAbstract:Ninety-five patients with papillary thyroid carcinoma (PTC) who received primary surgical treatment in 1983 at Kuma Hospital and were followed until 1992 were the subjects of this study. Initial therapy was tumor resection for 5 patients, lobectomy for 23 patients, total thyroidectomy with unilateral modified neck dissection for 60 patients, and total thyroidectomy with bilateral modified neck dissection for 7 patients. Clinical stage at diagnosis was as follows. Class I included 28 patients with intrathyroidal disease, class II included 60 patients with positive cervical lymph nodes, and class II included 7 patients with tumor invasion into tissue outside of the thyroid gland. Recurrence of the tumor was evaluated according to Lymphocytic Infiltration in the thyroid gland. Group A consisted of 36 patients with PTC associated with Lymphocytic Infiltration, 26 with Infiltration surrounding the tumor, 3 with Infiltration inside of the tumor, and 7 with both. Group B consisted of the remaining 59 patients with PTC with no Lymphocytic Infiltration. There were no differences in age, sex, initial tumor size, or initial treatment between groups A and B. Antithyroglobulin antibody and/or antimicrosomal antibody were positive in 16 patients from group A and 4 patients from group B (P < 0.001). Class I included 14 patients from each group, class II included 22 patients from group A and 38 patients from group B, and class III included 7 patients, all from group B. Recurrence of the tumor was found in only 1 group A patient (2.8%), but in 11 patients of group B (18.6%). The percentage of patients free from recurrence over the 10 yr of follow-up in group A was significantly higher than that in group B (by Cox-Mantel test, P < 0.01). The time between initial treatment and recurrence was 2-10 yr. In comparing the clinical stage at the time of initial treatment, recurrence was found in 1 class II patient from group A (4.5%) and in 1 class I (7.1%), 6 class II (15.8%), and 4 class III (57.1%) patients from group B. No patients died during the 10 yr of follow-up. In conclusion, 1) Lymphocytic Infiltration surrounding the tumor or inside the tumor in PTC might be of use as a means for predicting a favorable prognosis; and 2) class II or class III patients with no Lymphocytic Infiltration had a high rate of recurrence.
Flora Zagouri - One of the best experts on this subject based on the ideXlab platform.
-
Lymphocytic Infiltration and chemotherapy response score as prognostic markers in ovarian cancer patients treated with neoadjuvant chemotherapy
Gynecologic Oncology, 2020Co-Authors: Michalis Liontos, Maria Sotiropoulou, Maria Kaparelou, Kimon Tzannis, George Tsironis, Anastasios Kyriazoglou, Anna Tsiara, Roubini Zakopoulou, Konstantinos Koutsoukos, Flora ZagouriAbstract:Abstract Neoadjuvant Chemotherapy (NACT) followed by Interval Debulking Surgery (IDS) is an accepted frontline treatment in patients with advanced Epithelial Ovarian Cancer (EOC). Histopathologic assessment of tumor post NACT may provide a surrogate for response to treatment. The present study aims to characterize the pathological response and to examine its prognostic significance in these patients. Medical records of women with EOC treated in our institution from 2011 to 2016 were retrospectively identified. IDS specimens were reviewed by study pathologist and Chemotherapy Response Score (CRS), Lymphocytic Infiltration, necrosis and mitosis were assessed. 55 patients with EOC treated with NACT were identified and 48 had complete clinical and pathological data. Median age was 63 years. CRS assessed at omentum predicted PFS when adjusted for age, stage, debulking status (complete, optimal, suboptimal) and post IDS bevacizumab administration (mPFS CRS 1 vs 2 vs 3: 10.3–14–18.7 months 95% CI [7.4–15.7], [12.2–22.9], [13.5–31.3]). Presence of Lymphocytic Infiltration was associated with improved OS (log-rank test P = 0.015). Post IDS bevacizumab was associated with shorter PFS in patients with Lymphocytic Infiltration. BRCA status was known for 25 patients and presence of BRCA1/2 mutations was strongly correlated with Lymphocytic Infiltration (P = 0.011) but not CRS omentum (P = 0.926). Our study confirms the predictive value of CRS in EOC patients treated with NACT and IDS, but also demonstrates the prognostic significance of Lymphocytic Infiltration as well as its possible interaction with bevacizumab treatment.
Maria Sotiropoulou - One of the best experts on this subject based on the ideXlab platform.
-
217 the impact of chemotherapy response score and Lymphocytic Infiltration in patients with ovarian cancer treated with neoadjuvant chemotherapy
International Journal of Gynecologic Cancer, 2021Co-Authors: I Rodolakis, Michalis Liontos, Maria Sotiropoulou, Anastasia Prodromidou, Dimitrios Haidopoulos, A Bamias, Dimitrios Loutradis, N Thomakos, A RodolakisAbstract:Introduction/Background* Neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) represents an alternative approach to primary debulking for the management of advanced epithelial ovarian cancer (EOC) with comparable survival outcomes. Histopathologic examination of the IDS specimens and the evaluation of Chemotherapy Response Score (CRS) have been proposed as significant markers of response to NACT. The aim of the prsent study was to evaluate the prognostic significance of CRS in OC patients treated with NACT. Methodology A single institution retrospective analysis of patients with OC stage ≥III who were selected to receive NACT from 2011 to 2018 was performed. Omental and ovarian samples were assessed for the evaluation of CRS according to International Collaboration on Cancer Reporting (ICCR) recommendation. Lymphocytic Infiltration, presence of necrosis and mitotic index were also assessed. Result(s)* The final analysis included a total of 60 patients with median age of 65 years at diagnosis. Omentum and ovarian samples of the included patients revealed a CRS 3 in 20 and 10 patients, respectively. Patients with CRS3 at omentum had significantly prolonged median progression free survival (PFS) compared to CRS1 and CRS2 (19 vs 10 vs 15 months, respectively, p=0.002), while no difference was observed in the respective OS among the groups (42 vs 28 vs 32.3 months, respectively). Lymphocytic Infiltration in pre-treatment biopsies was related to improved PFS and OS (log-rank p =0.01 and p=0.015, respectively). No effect on either PFS or OS was observed in patients who received bevacizumab post-IDS, while in patients with Lymphocytic Infiltration bevacizumab negatively affected PFS. Conclusion* CRS seems to play a key role in the prediction of the postoperative course of EOC patients who received NACT and IDS. However, further studies are warranted to decipher the exact role of CRS and Lymphocytic Infiltration so as to personalize the treatment of EOC patients.
-
Lymphocytic Infiltration and chemotherapy response score as prognostic markers in ovarian cancer patients treated with neoadjuvant chemotherapy
Gynecologic Oncology, 2020Co-Authors: Michalis Liontos, Maria Sotiropoulou, Maria Kaparelou, Kimon Tzannis, George Tsironis, Anastasios Kyriazoglou, Anna Tsiara, Roubini Zakopoulou, Konstantinos Koutsoukos, Flora ZagouriAbstract:Abstract Neoadjuvant Chemotherapy (NACT) followed by Interval Debulking Surgery (IDS) is an accepted frontline treatment in patients with advanced Epithelial Ovarian Cancer (EOC). Histopathologic assessment of tumor post NACT may provide a surrogate for response to treatment. The present study aims to characterize the pathological response and to examine its prognostic significance in these patients. Medical records of women with EOC treated in our institution from 2011 to 2016 were retrospectively identified. IDS specimens were reviewed by study pathologist and Chemotherapy Response Score (CRS), Lymphocytic Infiltration, necrosis and mitosis were assessed. 55 patients with EOC treated with NACT were identified and 48 had complete clinical and pathological data. Median age was 63 years. CRS assessed at omentum predicted PFS when adjusted for age, stage, debulking status (complete, optimal, suboptimal) and post IDS bevacizumab administration (mPFS CRS 1 vs 2 vs 3: 10.3–14–18.7 months 95% CI [7.4–15.7], [12.2–22.9], [13.5–31.3]). Presence of Lymphocytic Infiltration was associated with improved OS (log-rank test P = 0.015). Post IDS bevacizumab was associated with shorter PFS in patients with Lymphocytic Infiltration. BRCA status was known for 25 patients and presence of BRCA1/2 mutations was strongly correlated with Lymphocytic Infiltration (P = 0.011) but not CRS omentum (P = 0.926). Our study confirms the predictive value of CRS in EOC patients treated with NACT and IDS, but also demonstrates the prognostic significance of Lymphocytic Infiltration as well as its possible interaction with bevacizumab treatment.
